INTRODUCTION

Portal hypertension (PH) is a major consequence of chronic liver disease that can lead to serious complications, such as variceal bleeding and ascites.\(^1,2\) PH is responsible for significant morbidity and mortality, particularly in patients with decompensated cirrhosis.\(^3,4\) In this regard, the diagnosis and precise discrimination of PH severity allow prediction of prognosis and essential for managing chronic liver disease (CLD) appropriately. Measurement of the hepatic venous pressure gradient (HVPG) has been accepted as the gold standard for assessing the degree of PH. Clinically significant PH (CSPH) defined as HVPG ≥10 mmHg, has been associated with
formation of esophageal varices and poor prognosis. However, the routine use of this method in clinical setting has been limited by its invasiveness and the need for expertise and specialized equipment.

Therefore, an alternative, non-invasive technique allowing clinicians to diagnose and grade PH in patients with cirrhosis and that could replace HVPG is needed. Transient elastography (TE) has been established as a non-invasive method of measuring liver stiffness due to its diagnostic accuracy in hepatic fibrosis. Accumulating evidence suggests that TE adequately reflects the findings of HVPG, indicating that it is a useful modality for evaluating PH and cirrhotic complications. However, some studies have reported conflicting results indicating TE is not sufficiently accurate to replace HVPG due to its insufficient sensitivity or specificity. Hence, controversy remains regarding the usefulness of TE for assessing PH. Systematic reviews (SRs) and meta-analyses (MAs) have facilitated objective evaluation of existing evidence. Shi et al. reported the results of their MA for TE in the diagnosis of PH and esophageal varices and further studies should be performed to confirm their conclusion.

Thus, the present SR and MA identified the clinical usefulness of non-invasive TE for assessing PH as an alternative to HVPG in patients with CLD.

**MATERIALS AND METHODS**

**Literature search**

We performed a literature search to identify published study articles that examined TE for the diagnosis of PH in patients with CLD. We searched Ovid Medline, the Cochrane Library and EBASE for the studies published prior to December 30, 2015, using the following search terms: elastography, liver stiffness, portal hypertension, chronic liver disease and diagnostic test. Then, a manual search of the reference lists of the primary studies was performed to locate any other studies. The present study was performed according to the PRISMA Statement.

**Study inclusion/exclusion**

The inclusion criteria for primary studies were as follows: (1) studies that evaluated the accuracy of liver stiffness performed using TE for the prediction of PH in patients with CLD; (2) studies that measured portal pressure using the HVPG; PH defined as ≥6 mmHg, CSPH ≥10 mmHg and severe PH ≥12 mmHg; (3) studies that reported the data necessary to calculate the true positive, false positive, true negative and false negative diagnostic results of TE for the diagnosis of PH, significant PH and severe PH based on cut-off values. If such data were unavailable, the corresponding author was contacted.

**Quality assessment of the primary studies**

The quality of the studies included in the MA was assessed using the Quality Assessment of Diagnostic Accuracy Studies (QUADAS) questionnaire, which was designed to assess the internal and external validity of the diagnostic accuracy of studies in this analysis. This tool is a 14-item instrument that allows the identification of important design elements in diagnostic accuracy studies, such as the patient spectrum, the presence or absence of observer blinding and verification bias, the handling of indeterminate results and the reporting of patients lost to follow-up. Each study that met the inclusion criteria was analyzed by two independent reviewers. Discrepancies in the results were handled by a consensus review. If the QUADAS score was less than 10 points, the study was classified as having low methodological quality.

**Data extraction**

Two reviewers independently extracted required information from the primary studies based on a fixed protocol. In each study, the following information was obtained: author; study publication year; country; study design; number of patients; patient age and sex; CLD etiology; prevalence of PH and significant PH; TE cut-off for PH; number of true positives, false positives, true negatives, and false negatives; sensitivity; specificity; positive predictive value; negative predictive value; area under the receiver operating characteristic curve (AUROC); and correlation coefficient estimate.

**Data analysis/synthesis**

The integrated results of each study were presented to show their combined effect, measured as summary sensitivity values, specificity values, likelihood ratios and summary correlations with 95% confidence interval (CI) used to examine the TE accuracy for PH. The effect size regarding the correlation coefficient between TE and HVPG was calculated with transformation using Fisher’s Z. Correlation forest and radial plots were also constructed to determine the diagnostic accuracy of the test parameters.
The heterogeneity of all diagnostic test parameters was initially evaluated with a graphic examination of forest plots for each parameter. Then, a statistical assessment was performed with the inconsistency index (I^2). The I^2 statistic was defined as the percentage of variability due to heterogeneity beyond that from chance; values >50% represented the possibility of substantial heterogeneity.

Finally, publication bias analysis and sensitivity analysis were conducted to verify the validity of the results. The analyses were performed using Review Manager (RevMan) version 5.3 (The Cochrane Collaboration, London, UK), comprehensive meta-analysis software version 3.0 (Biostat, Inc., Englewood, NJ, USA) and R statistical software (The R Foundation, Vienna, Austria).

RESULTS

Characteristics of studies in our analysis

Based on the described search strategies, 163 studies were retrieved. After eliminating the duplicates (n=86) or studies that were unrelated to the topic (n=35), 42 potentially relevant studies were identified for further evaluation. Ultimately, 34 studies were excluded for undesirable article type (n=17), not written in English (n=1), failing to evaluate TE accuracy (n=7), irrelevant to CLD (n=7), or containing insufficient data (n=2). Thus, eight studies fulfilled the inclusion criteria. The flow chart of the study selection is shown in Figure 1.

The main study characteristics included in this analysis are summarized in Table 1; 1,356 patients (mean age: 55.1 years, 69.2% male) were included. The overall prevalence of PH, significant PH and severe PH were 59.4% (range: 46.0-72.9%), 58.3% (range: 21.7-80.4%), and 58.9% (range: 57.4-60.5%), respectively.

Based on the QUADAS scale, the included studies had very good methodological quality (Table 1).

Accuracy of TE for the detection of PH/CSPH/severe PH

Two studies evaluated the diagnostic accuracy of TE for PH (Table 2). The cut-off value of liver stiffness ranged from 8-8.74 kPa. The sensitivity and specificity were 0.88 (range: 0.86-0.90) and 0.74 (range: 0.67-0.81), respectively. The positive predictive value (PPV) and negative predictive value (NPV) were 0.83 (range: 0.81-0.84) and 0.88 (range: 0.85-0.90), respectively. The AUROC for the diagnosis of PH (HVPG ≥ 6 mmHg) was 0.86 (range: 0.79-0.92). One study reported a significant correlation between TE and HVPG for the diagnosis of PH (r=0.84, P<0.001).

A forest plot of the eight studies showed pooled correlation between HVPG and TE (Figs. 2 and 3). Five studies demonstrated a relationship between TE and HVPG for the diagnosis of CSPH and a significant correlation was observed with an effect size of correlation (COR) 0.7480 (95% CI, 0.6464; 0.8236, P<0.0001)
### Table 1. The main characteristics of studies evaluating the performance of TE for detection of portal hypertension, clinically significant portal hypertension, and severe portal hypertension

| First author, public year, [Ref. no.] | Study design | Country | No. of index cases (sex M:F), mean age, years | Etiology | Prevalence of % (n) | Child A (%) | BMI (kg/m²) | QUADAS score | TE cut-off (kPa) |
|--------------------------------------|--------------|---------|---------------------------------------------|----------|---------------------|------------|-------------|--------------|-----------------|
|                                      |              |         |                                             |          |                     |            |             |              | PH ≥ 6 mm Hg | CSPH ≥ 10 mm Hg | Severe ≥ 12 mm Hg | PH | CSPH | Severe |
| Vizzutti et al. [8] (2007)            | Prospective  | Italy   | 61 (39:22), 55.6±11.7                      | CLD (61 HCV) | 77.1 (47) | 57.4 (35) | 459 | 23±3 | 11 | ≥13.6 | ≥176 |
| Lemoine et al. [9] (2008)            | Retrospective| France  | 92 (64:28), 56.0±13.0                      | CLD (44 HCV-related cirrhosis, 48 alcohol-related cirrhosis) | 80.4 (74) | HCV 77.0 (34) | alcohol 83.3 (40) | 100 | NR | 13 | HCV 20.5 | alcoholic 34.9 |
| Bureau et al. [10] (2008)           | Prospective  | France  | 150 (90:60), median: 55.0 (inter-quartile range: 45-65) | CLD (51 alcohol, 46 viral hepatitis, 7 alcohol + virus, 11 NASH, 10 autoimmune hepatitis, 6 cholestatic disease, 19 miscellaneous) | 51.3 (76) | 20.0 | 24.4 | 13 | 210 |
| Sánchez-Conde et al. [11] (2011)    | Prospective  | Spain   | 38 (24:14), 470 (range: 42-49)              | CLD (38 HIV/HCV-coinfection) | 73.7 (28) | 60.5 (23) | 71.05 | NR | 10 | ≥14.0 | ≥2.30 |
| Carrón et al. [12] (2006)           | Prospective  | Spain   | 124 (82:42), Median: 60 (range: 35-73)      | HCV-infected liver transplant recipients HCV-LT | 46.0 (60) | 21.7 (27) | NR | 25 (range: 17–35) | 12 | ≥8.74 | ≥18.0 |
| Reiberger et al. [13] (2012)         | Prospective  | Austria | 695 (497:198), 50±12                       | CLD (390 viral hepatitis, 227 alcoholic liver disease, 31 autoimmune hepatitis, 47 nonalcoholic steatohepatitis) | 72.9 (366/502) | 55 (276/502) | NR | 23.1 | 12 | ≥8 | ≥18.0 | ≥20 | ≥23 |
| Berzigotti et al. [14] (2013)        | Prospective  | Italy   | 117 (82:35), 60±11                          | CLD (78 HIV 11 HBV, 16 alcohol, 12 other) | 67 (78) | 88.0 | 26.8±4.7 | 12 | ≥13.6 | ≥21.1 |
| Llop et al. [15] (2012)              | Prospective  | Spain   | 79 (60:19), 62.0 (range: 41-80)             | CLD (52 HCV, 8 alcohol, 10 HBV, 4 hemochromatosis, 3 NASH, 2 cryptogenic) | 40.5 (32) | 100 | NR | 14 | ≥13.6 | ≥21 |

TE, transient elastography; M, male; F, female; PH, portal hypertension; CSPH, clinically significant PH; BMI, body mass index; QUADAS, Quality Assessment of Diagnostic Accuracy Studies; CLD, chronic liver disease; HCV, hepatitis C virus; NASH, nonalcoholic steatohepatitis; HIV, human immunodeficiency virus; NR, normal range; LT, liver transplantation; HBV, hepatitis B virus.
according to the random effects model (Figs. 2 and 3). The I² statistic value was 84.7%, indicative of substantial heterogeneity caused by the inconsistent characteristics of the included studies, including patient characteristics, cirrhosis etiologies, and varying diagnostic thresholds.

Eight studies\(^8\)\(^{-15}\) evaluated the diagnostic accuracy of TE for CSPH (Table 2). The cut-off value of liver stiffness ranged from 13.6-21.0 kPa (alcoholic 19-34.9 kPa). The sensitivity and specificity were 0.85 (range: 0.63-0.97) and 0.71 (range: 0.50-0.93), respectively. The PPV and NPV were 0.84 (range: 0.56-0.97) and 0.76 (range: 0.35-0.92), respectively. The AUROC for the diagnosis of CSPH (HVPG \(\geq\) 10 mmHg) was 0.88 (range: 0.76-0.99).

Five studies\(^8\)\(^{-11},13\)\(^{-15}\) evaluated the diagnostic accuracy of TE for severe PH (Table 2). The cut-off value of liver stiffness varied from 17.6-23.0 kPa (alcoholic 23.0 kPa). The sensitivity and specificity were 0.76 (range: 0.53-0.94) and 0.82 (range: 0.67-0.92), respectively. The PPV and NPV were 0.85 (range: 0.79-0.95) and 0.76 (range: 0.58-0.91), respectively. The AUROC for the diagnosis of CSPH (HVPG \(\geq\) 12 mmHg) was 0.85 (range: 0.79-0.92).

**Assessment of publication bias and sensitivity analysis**

We used a funnel plot to examine publication bias. The results of the MA showed a symmetrical shape for pooled correlation in 5 studies. The adjusted pooled correlation calculated using the trim-and-fill method was 0.80 (95% CI, 0.71; 0.86, \(P<0.0001\)), which was slightly higher than the observed effect size of 0.75 (95% CI, 0.65; 0.82, \(P<0.0001\)), but it had no major impact on this study (Fig. 4).

We performed sensitivity analysis to assess the extent to which our results were sensitive to the analysis restricted only to those studies. No significant difference was found for the pooled results of any of the assessed outcomes.

**DISCUSSION**

The objective of this SR and MA was to identify the clinical usefulness of non-invasive TE for assessing PH in patients with CLD. There has been considerable interest in developing and validating non-invasive methods to detect PH among patients with cirrhosis.\(^5\)\(^{-15},17\) Accordingly, this review can help researchers compare and select the most appropriate non-invasive evaluations for PH...
To the best of our knowledge, this is the first SR and MA to focus on the utility of measuring TE for diagnosing PH by thorough comparison with HVPG in CLD. Although a Chinese group presented the MA results of TE for diagnosing PH and the presence of esophageal varices, only five published studies have evaluated the performance of TE for significant PH in a small number of patients, limiting the robustness of any conclusion reached. In addition, considerable variability existed across different investigations as well as small sizes of individual studies. However, more accumulating data are now available, allowing a more precise analysis of TE versus HVPG for diagnosing PH.

TE has the advantage of being non-invasive and many attempts have been made to assess the degree of hepatic fibrosis using TE. Recently, several lines of evidence have indicated that TE can be useful for assessing the severity of PH.8-15 This systematic review identified eight studies that evaluated the diagnostic performance of TE with PH in patients with cirrhosis and fulfilled the inclusion criteria and reported sufficient data.

The diagnostic accuracy of TE for CSPH was high in the present SR and MA (COR 0.7480, 95% CI, 0.6464; 0.8236, \( P < 0.0001 \)). Furthermore, the sensitivity and specificity were 0.85 (range: 0.63-0.97) and 0.71 (range: 0.50-0.93), respectively; the AUROC was 0.88 (range: 0.76-0.99).

However, Llop et al.15 demonstrated a moderate correlation between TE and HVPG (\( r = 0.552 \)) compared to other studies (\( r = 0.68-0.86 \)). Furthermore, patients with a TE value between 13.6 and 21 kPa had insufficient sensitivity and specificity to detect CSPH (HVPG >10 mmHg). The reason for this varying performance of TE might be that only less severe forms of CLD, such as Child-Pugh A with hepatoma, were included, since this is the target population for identifying CSPH in patients with potentially resectable hepatomas. Most of the studies on patients without hepatoma showed a higher correlation between TE and HVPG than the studies evaluated in this study. Accordingly, the presence of hepatoma and the Child A population in this study were attributed to different results obtained using TE.

Since PH is initiated by an increase in intrahepatic resistance, TE appropriately reflects mild to moderate PH or the initiation of CSPH. However, in cases of severe PH, its severity becomes more dependent on the amount of portal blood inflow and peripheral hemodynamic changes than the stiffness of the hepatic parenchyma; thus, the predictive power of TE for PH is limited.8 This expla-

Table 2. Summary accuracy of TE detection of PH, clinically significant PH, and severe PH

| TE detection | Studies, N | Etiology | TE cut-off | Se   | Sp   | PPV   | NPV   | AUROC |
|--------------|-----------|----------|------------|------|------|-------|-------|-------|
| Portal hypertension | 2 Total | ≥8.0-8.74 | 0.88 (0.86-0.90) | 0.74 (0.67-0.81) | 0.83 (0.81-0.84) | 0.88 (0.85-0.90) | 0.86 (0.79-0.92) |
| 1 Alcoholic | ≥10 | 0.85 | 0.79 | 0.86 | 0.75 | 0.74 (0.70-0.76) |
| Significant portal hypertension | 8 Total | ≥13.6-21.0 | 0.87 (0.63-0.97) | 0.71 (0.50-0.93) | 0.84 (0.56-0.97) | 0.76 (0.35-0.92) | 0.88 (0.76-0.99) |
| 3 Alcoholic | ≥19.0-34.9 | 0.90 (0.89-0.90) | 0.81 (0.73-0.88) | 0.94 (0.89-0.98) | 0.74 (0.64-0.84) | 0.88 (0.80-0.94) |
| Severe portal hypertension | 5 Total | ≥17.6-23.0 | 0.76 (0.53-0.94) | 0.82 (0.67-0.92) | 0.85 (0.79-0.95) | 0.76 (0.58-0.91) | 0.85 (0.79-0.92) |
| 1 Alcoholic | ≥23.0 | 0.91 | 0.77 | 0.87 | 0.80 | 0.79 (0.73-0.86) |

TE, transient elastography; PH, portal hypertension; PPV, positive predictive value; NPV, negative predictive value; AUROC, area under the receiver operating characteristic curve.

Figure 4. Trim and fill funnel plot on the pooled correlation.

in patients with CLD.

To the best of our knowledge, this is the first SR and MA to focus on the utility of measuring TE for diagnosing PH by thorough comparison with HVPG in CLD. Although a Chinese group presented the MA results of TE for diagnosing PH and the presence of esophageal varices, only five published studies have evaluated the performance of TE for significant PH in a small number of patients, limiting the robustness of any conclusion reached.21 In addition, considerable variability existed across different investigations as well as small sizes of individual studies. However, more accumulating data are now available, allowing a more precise analysis of TE versus HVPG for diagnosing PH.

TE has the advantage of being non-invasive and many attempts have been made to assess the degree of hepatic fibrosis using TE. Recently, several lines of evidence have indicated that TE can be useful for assessing the severity of PH.8-15 This systematic review identified eight studies that evaluated the diagnostic performance of TE with PH in patients with cirrhosis and fulfilled the inclusion criteria and reported sufficient data.

The diagnostic accuracy of TE for CSPH was high in the present SR and MA (COR 0.7480, 95% CI, 0.6464; 0.8236, \( P < 0.0001 \)). Furthermore, the sensitivity and specificity were 0.85 (range: 0.63-0.97) and 0.71 (range: 0.50-0.93), respectively; the AUROC was 0.88 (range: 0.76-0.99).

However, Llop et al.15 demonstrated a moderate correlation between TE and HVPG (\( r = 0.552 \)) compared to other studies (\( r = 0.68-0.86 \)). Furthermore, patients with a TE value between 13.6 and 21 kPa had insufficient sensitivity and specificity to detect CSPH (HVPG >10 mmHg). The reason for this varying performance of TE might be that only less severe forms of CLD, such as Child-Pugh A with hepatoma, were included, since this is the target population for identifying CSPH in patients with potentially resectable hepatomas. Most of the studies on patients without hepatoma showed a higher correlation between TE and HVPG than the studies evaluated in this study. Accordingly, the presence of hepatoma and the Child A population in this study were attributed to different results obtained using TE.

Since PH is initiated by an increase in intrahepatic resistance, TE appropriately reflects mild to moderate PH or the initiation of CSPH. However, in cases of severe PH, its severity becomes more dependent on the amount of portal blood inflow and peripheral hemodynamic changes than the stiffness of the hepatic parenchyma; thus, the predictive power of TE for PH is limited.8 This expla-
nation was supported since TE could not accurately predict the hemodynamic response to a non-selective B blocker.

The currently favored method for determining portal venous pressure involves catheterization of the hepatic vein and measurement of HVPG, which provides independent prognostic information on survival and the risk of decompensation. CSPH is also necessary for esophageal varix formation, bleeding and initial decompensation.5-7

Although HVPG is the most accurate test for diagnosing PH, a readily available, non-invasive method is preferable for the assessment of PH because most of the patients with CLD require long-term follow-up. This study demonstrated that due to the correlation between TE and HVPG, TE can potentially reduce the number of HVPG procedures performed in order to examine the severity of PH.8-15

The present study had the following potential limitations. First, only eight studies were used to evaluate the usefulness and performance of TE, thus limiting the robustness of the conclusions reached. Second, the characteristics of the included studies, including patient characteristics, cirrhosis etiologies and varying diagnostic thresholds, were not completely consistent. Third, we only included studies written in English, thus language bias might have influenced the results.

In conclusion, the TE results were similar to those obtained using HVPG. Additionally, TE is a simple and safe method due to its non-invasiveness. Although further investigation is needed, TE could be a reliable, non-invasive supplementary tool for diagnosing the severity of PH.

Authors’ contributions

GK and SKB designed the analysis. MYK and SKB formulated the model. GEK and SKB analyzed the data. GK and SKB wrote the manuscript. All authors reviewed and approved the manuscript.

Acknowledgements

This study was supported by a grant from the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health and Welfare, Republic of Korea (HI15C2364) and by the Yonsei University Future-Leading Research Initiative of 2014.

Conflicts of Interest

The authors have no conflicts to disclose.

REFERENCES

1. Kim MY, Cho MY, Baik SK, Park HJ, Jeon HK, Im CK, et al. Histological subclassification of cirrhosis using the Laennec fibrosis scoring system correlates with clinical stage and grade of portal hypertension. J Hepatol 2011;55:1004-1009.
2. Jang YO, Jun BG, Baik SK, Kim MY, Kwon SO. Inhibition of hepatic stellate cells by bone marrow-derived mesenchymal stem cells in hepatic fibrosis. Clin Mol Hepatol 2015;21:141-149.
3. Eom YW, Shim KY, Baik SK. Mesenchymal stem cell therapy for liver fibrosis. Korean J Intern Med 2015;30:580-589.
4. Eom YW, Kim G, Baik SK. Mesenchymal stem cell therapy for cirrhosis: present and future perspectives. World J Gastroenterol 2015;21:10253-10261.
5. Baik SK. Haemodynamic evaluation by Doppler ultrasonography in patients with portal hypertension: a review. Liver Int 2010;30:1403-1413.
6. Kim MY, Suk KT, Baik SK, Kim HA, Kim YJ, Cha SH, et al. Hepatic vein arrival time as assessed by contrast-enhanced ultrasonography is useful for the assessment of portal hypertension in compensated cirrhosis. Hepatology 2012;56:1053-1062.
7. Kim MY, Jeong WK, Baik SK. Invasive and non-invasive diagnosis of cirrhosis and portal hypertension. World J Gastroenterol 2014;20:4300-4315.
8. Vizzutti F, Arena U, Romanelli RG, Rega L, Foschi M, Colagrande S, et al. Liver stiffness measurement predicts severe portal hypertension in patients with HCV-related cirrhosis. Hepatology 2007;45:1290-1297.
9. Lemoine M, Katsahian S, Ziol M, Nahon P, Ganne-Carrie N, Kazemi F, et al. Liver stiffness measurement as a predictive tool of clinically significant portal hypertension in patients with compensated hepatitis C virus or alcohol-related cirrhosis. Aliment Pharmacol Ther 2008;28:1102-1110.
10. Bureau C, Metivier S, Peron JM, Selves J, Robic MA, Gourraud PA, et al. Transient elastography accurately predicts presence of significant portal hypertension in patients with chronic liver disease. Aliment Pharmacol Ther 2008;27:1261-1268.
11. Sánchez-Conde M, Miralles P, Bellón JM, Rincón D, Ramirez M, Gutiérrez I, et al. Use of transient elastography (FibroScan®) for the noninvasive assessment of portal hypertension in HIV/HCV-infected patients. J Viral Hepat 2011;18:685-691.
12. Carrón JA, Navasa M, Bosch J, Bruguera M, Gilabert R, Forns X. Transient elastography for diagnosis of advanced fibrosis and portal hypertension in patients with hepatitis C recurrence after liver transplantation. Liver Transpl 2006;12:1791-1798.
13. Reiberger T, Ferlitsch A, Payer BA, Pinter M, Schwabl P, Stift J, et al. Noninvasive screening for liver fibrosis and portal hypertension by transient elastography—a large single center experience. Wien Klin
Wochenschr 2012;124:395-402.
14. Berzigotti A, Seijo S, Arena U, Abraldes JG, Vizzutti F, García-Pagán JC, et al. Elastography, spleen size, and platelet count identify portal hypertension in patients with compensated cirrhosis. Gastroenterology 2013;144:102-111.e1.
15. Llop E, Berzigotti A, Reig M, Eric E, Reverter E, Seijo S, et al. Assessment of portal hypertension by transient elastography in patients with compensated cirrhosis and potentially resectable liver tumors. J Hepatol 2012;56:103-108.
16. Kim G, Baik SK. Overview and recent trends of systematic reviews and meta-analyses in hepatology. Clin Mol Hepatol 2014;20:137-150.
17. Kim G, Cho YZ, Baik SK, Kim MY, Hong WK, Kwon SO. The accuracy of ultrasonography for the evaluation of portal hypertension in patients with cirrhosis: a systematic review. Korean J Radiol 2015;16:314-324.
18. Kim G, Cho YZ, Baik SK. Assessment for risk of bias in systematic reviews and meta-analyses in the field of hepatology. Gut Liver 2015;9:701-706.
19. Kim G, Eom YW, Baik SK, Shin Y, Lim YL, Kim MY, et al. Therapeutic effects of mesenchymal stem cells for patients with chronic liver diseases: Systematic review and meta-analysis. J Korean Med Sci 2015;30:1405-1415.
20. Kim G, Lee SS, Baik SK, Cho YZ, Kim MY, Kwon SO, et al. The need for histological subclassification of cirrhosis: a systematic review and meta-analysis. Liver Int 2016;36:847-855.
21. Shi KQ, Fan YC, Pan ZZ, Lin XF, Liu WY, Chen YP, et al. Transient elastography: a meta-analysis of diagnostic accuracy in evaluation of portal hypertension in chronic liver disease. Liver Int 2013;33:62-71.
22. Higgins JPT, Green S. Cochrane handbook for systematic reviews of interventions. Vol 4. Hoboken: John Wiley & Sons, 2011.